Radiopharm Theranostics Limited Sponsored ADR RADX 深 沪
等待开盘 03-27 09:30:00 美东时间
4.25
-0.080
-1.85%
华盛通- 最 高5.12
- 今 开4.05
- 成交量 10.98万股
- 最 低 3.90
- 昨 收 4.33
- 总市值 0
- 52周最高 16.25
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 3.50
- 委 比 99.14%
- 总股本 --
- 历史最高 50.82
- 量 比 0
- 振 幅 28.18%
- 历史最低 3.50
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with final readout expected by June.
03-24 22:56
Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial
Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
03-24 19:14
Radiopharm Theranostics Doses First Participant In Phase 1/2 Clinical Study Of 177Lu-Betabart
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
02-24 20:36
Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
2025-12-20 21:31
Dow Falls 50 Points; US Adds 64,000 Jobs In November
U.S. stocks traded mostly lower this morning, with the Dow Jones index falling ...
2025-12-16 22:56
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.
2025-12-16 00:59
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With
2025-12-15 20:26
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Radiopharm Theranostics' RAD101 has received FDA Fast Track Designation to differentiate between recurrent brain metastases and treatment effects in a Phase 2 clinical trial.
2025-06-11 12:00
Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Radiopharm Theranostics has dosed the first patient in a Phase 1 trial of 177Lu-RAD202, targeting HER2-positive advanced solid tumors. The 'HEAT' trial aims to assess safety, tolerability, and efficacy of this novel radiotherapeutic, with earlier data supporting its potential. The study is conducted across Australia, targeting patients with aggressive cancers like breast, ovarian, and gastric. This milestone underscores the company's commitment to addressing unmet needs in oncology.
2025-06-04 12:00
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Radiopharm Theranostics announced favorable preclinical data for RV01, a B7-H3-targeted radiopharmaceutical, showing high tumor uptake and favorable biodistribution. The modified monoclonal antibody has a shorter half-life, reducing off-target exposure and potential toxicities. IND submission is expected mid-2025, with a first-in-human Phase 1 study planned for Q4 2025.
2025-06-02 12:00
